- FDA Approves Trabectedin for Sarcoma🔍
- U.S. FDA Approves YONDELIS® 🔍
- FDA Approves New Therapeutic for Treating Certain Soft Tissue ...🔍
- FDA Approves Trabectedin for Certain Types of Advanced Soft ...🔍
- Trabectedin for Soft Tissue Sarcoma🔍
- FDA Approval Summary🔍
- FDA Approves Trabectedin in Soft Tissue Sarcomas🔍
- New Therapeutic for Treating Certain Soft Tissue Sarcomas🔍
FDA Approves Trabectedin for Two Soft Tissue Sarcomas
FDA Approves Trabectedin for Sarcoma - NCI
On October 23, the Food and Drug Administration (FDA) approved trabectedin (Yondelis®) for the treatment of two subtypes of soft tissue ...
U.S. FDA Approves YONDELIS® (trabectedin) for the Treatment of ...
today announced the U.S. Food and Drug Administration (FDA) has approved YONDELIS® (trabectedin) for the treatment of patients with unresectable ...
FDA Approves New Therapeutic for Treating Certain Soft Tissue ...
Specifically, trabectedin is approved for treating patients with liposarcoma and leiomyosarcoma that cannot be removed by surgery or that is ...
Yondelis (Trabectedin) Approved for the Treatment of Unresectable ...
Sarcomas, a group of malignant tumors that develop in soft tissue and bone, can affect any part of the body but most often occur in the abdomen, arms, ...
FDA Approves Trabectedin for Certain Types of Advanced Soft ...
The effectiveness and safety of Yondelis were demonstrated in 518 clinical trial participants with metastatic or recurrent leiomyosarcoma or ...
Trabectedin for Soft Tissue Sarcoma: Current Status and Future ...
Approval was based on the results of a pivotal Phase 3 trial involving a 2:1 randomization of 518 patients (who were further stratified by soft tissue sarcoma ...
FDA Approval Summary: Trabectedin for Unresectable or Metastatic ...
Liposarcoma and leiomyosarcoma represent 40% to 50% of all cases of unresectable or metastatic soft-tissue sarcoma (STS). Approximately 12,310 new cases of ...
FDA Approves Trabectedin in Soft Tissue Sarcomas - OncLive
The FDA has approved trabectedin for the treatment of patients with advanced soft tissue sarcoma, including liposarcoma and leiomyosarcoma ...
New Therapeutic for Treating Certain Soft Tissue Sarcomas
The FDA has approved trabectedin for the treatment of certain patients with two types of soft tissue sarcoma, liposarcoma and leiomyosarcoma.
FDA Approves Trabectedin (Yondelis) for Advanced Soft-Tissue ...
Trabectedin was first approved in Europe in 2007, and is indicated there for both soft-tissue sarcoma and for ovarian cancer. “Since Yondelis ...
FDA Approves Trabectedin for Two Soft Tissue Sarcomas - Medscape
FDA Approves Trabectedin for Two Soft Tissue Sarcomas ... The US Food and Drug Administration (FDA) has approved the chemotherapy trabectedin ( ...
Yondelis® Approved for Treatment of Soft Tissue Sarcoma
The United States Food and Drug Administration (FDA) approved the chemotherapy agent, Yondelis® (trabectedin), for the treatment of liposarcoma and ...
Yondelis (trabectedin) FDA Approval History - Drugs.com
Yondelis (trabectedin) is a cytotoxic antitumor agent for the treatment of unresectable or metastatic liposarcoma or leiomyosarcoma, two common subtypes of soft ...
FDA Approves Trabectedin in Soft Tissue Sarcoma | Physicians ...
The FDA has approved trabectedin (Yondelis) for the treatment of patients with unresectable or metastatic soft tissue sarcoma who have previously received ...
FDA approves trabectedin for some advanced soft tissue sarcomas
The Food and Drug Administration has approved trabectedin for the treatment of advanced or unresectable liposarcomas and leiomyosarcomas ...
U.S. FDA Approves YONDELIS® (trabectedin) for the Treatment of ...
today announced the U.S. Food and Drug Administration (FDA) has approved YONDELIS® (trabectedin) for the treatment of patients with unresectable ...
Trabectedin for Soft Tissue Sarcoma Approved by FDA
Advanced soft tissue sarcoma patients will now be able to receive trabectedin (Yondelis), which has been approved by the FDA after promising results from a ...
2. Reference ID: 5245893. Page 5. osteosarcoma, Ewing sarcoma, and non-rhabdomyosarcoma soft tissue sarcoma). No new safety signals were ...
Trabectedin Now FDA-Approved for Metastatic Soft Tissue Sarcomas
Trabectedin (Yondelis) chemotherapy was approved by the FDA for treatment of patients with specific metastatic soft tissue ...
FDA Approves New Therapy for Certain Types of Advanced Soft ...
The US Food and Drug Administration (FDA) today approved Yondelis (trabectedin), a chemotherapy, for the treatment of specific soft tissue ...